title: Fever development in neuroleptic malignant syndrome during treatment with olanzapine and clozapine.
abstract: Neuroleptic malignant syndrome (NMS) is the most dangerous life-threatening complication of antipsychotic medication. It's development is connected with the blockade of dopaminergic transmission (D2 receptors) in the nigrostriatal system of the brain. Fever is one of the main symptoms of this syndrome and it's elevation is due to the activation of the immune system. Numerous studies report that treatment with clozapine (doses 37.5-600 mg) or olanzapine (doses 10-25 mg) or the use of these drugs in polytherapy cause pyrexia between 37.8-40.6 °C. Additionally, levels of proinflammatory interleukins such as IL-6, IL-1,TNF-α were increased. The aim of this article is to describe how olanzapine and clozapine influence fever development in NMS, in relation to the dose of the drug taken by schizophrenic patients including changes in immunological system.
authors.affiliation: Department of Psychiatry, University Hospital, Kurpińskiego 19, PL 85-096 Bydgoszcz, Poland.
authors.forename: Anna
authors.initials: A
authors.lastname: Szota
authors.forename: Ewa
authors.initials: E
authors.lastname: Ogłodek
authors.forename: Aleksander
authors.initials: A
authors.lastname: Araszkiewicz
mesh_terms: D014150:Antipsychotic Agents / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D001569:Benzodiazepines / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D003024:Clozapine / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D004305:Dose-Response Relationship, Drug; D005334:Fever / Q000139:chemically induced* / Q000276:immunology; D006801:Humans; D018836:Inflammation Mediators / Q000378:metabolism; D007378:Interleukins / Q000378:metabolism; D009459:Neuroleptic Malignant Syndrome / Q000209:etiology* / Q000276:immunology; D000077152:Olanzapine; D012559:Schizophrenia / Q000188:drug therapy
chemical_list: D014150:Antipsychotic Agents; D018836:Inflammation Mediators; D007378:Interleukins; D001569:Benzodiazepines; D003024:Clozapine; D000077152:Olanzapine